MINI FUTURE SHORT - ELI LILLY & CO | Real-time Bid/Ask 02:23:21 27/06/2024 pm IST | ||
| 13.01 EUR / 13.16 EUR | -2.28% |
|
| Current month | -35.62% | ||
| 1 month | -37.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 13.05 | -2.54% |
| 26/24/26 | 13.39 | +1.52% |
| 25/24/25 | 13.19 | -5.45% |
| 24/24/24 | 13.95 | -6.12% |
| 21/24/21 | 14.86 | -1.13% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 01:04 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC68CQ |
| ISIN | DE000PC68CQ8 |
| Date issued | 25/03/2024 |
| Strike | 1,042 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 24.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.98 € |
|---|---|
| Lowest since issue | 12.6 € |
| Spread | 0.15 € |
| Spread % | 1.14% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
